4th Quarter - Amendment
BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.
Client
Income
—
Expenses
$280,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2026 | $270,000 | Replaced |
| 4th Quarter - Amendment (this page) | Jul 17, 2026 | $280,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Give Kids a Chance Act of 2025 - H.R. 1262; S 932 General issues and provisions related to PBM Reform ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA MALAKOFF | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.